Lilly has bought into Lycia's lysosomal targeting chimera (LYTAC) protein degradation technology, developed by Bertozzi at Stanford University, with an initial focus on projects in immunological ...

In drug discovery, targeted protein degradation is a method that selectively eliminates disease-causing proteins. A ...

The onset or progression of many refractory diseases, including neurodegenerative disorders and cancers, is caused by the accumulation of proteins. Targeted protein degradation (TPD) has emerged ...

A team of scientists has used a novel approach to identify protein degraders that target Pin1, a protein involved in pancreatic cancer development.

In drug discovery, targeted protein degradation is a method that selectively eliminates disease-causing proteins. A University of California, Riverside team of scientists has used a novel approach to ...